Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis-Relapsing-Remitting Clear all
Not yet recruiting Phase 2 Interventional

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

NCT07222956
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Interventions
Remibrutinib (Open Label)
Drug
Lead sponsor
Moein Amin
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis

NCT01081782
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ONO-4641, ONO-4641 placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Sep 12, 2026, 2:06 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

NCT07667322
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab Co-formulated With rHuPH20
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Carlsbad, California • Maitland, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
HB-adMSCs, Placebo
Biological · Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 12, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

NCT07510607
View directory record Official record
Conditions
Multiple Sclerosis, RRMS, Relapsing Remitting MS
Interventions
HP 13C pyruvate injection, MRI Scanner
Drug · Device
Lead sponsor
Ari Green
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00803049
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide (HMR1726)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
4
States / cities
Maitland, Florida • Fort Wayne, Indiana • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

NCT00220779
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Treatment Interruption of Natalizumab

NCT01071083
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

NCT01848327
View directory record Official record
Conditions
Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions
Caprylic Triglyceride, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 59 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 12, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

NCT00595920
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Interventions
Tovaxin
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 12, 2026, 2:06 AM EDT
Withdrawn No phase listed Observational

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

NCT01539395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MSDx Complex-1 Biomarker Test
Other
Lead sponsor
MSDx, Inc.
Industry
Eligibility
45 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 12, 2026, 2:06 AM EDT
Completed No phase listed Observational Results available

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

NCT03562975
View directory record Official record
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00509145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study

NCT02914964
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Swank Diet, Wahls Elimination Diet
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Natalizumab Re-Initiation of Dosing

NCT00306592
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BG00002 (natalizumab)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 12, 2026, 2:06 AM EDT
Not yet recruiting Not applicable Interventional

Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis

NCT04768777
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
Interventions
Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

NCT02499900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Copaxone®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 12, 2026, 2:06 AM EDT
Terminated Phase 1 Interventional

Oral Guanabenz for Multiple Sclerosis

NCT02423083
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Interventions
Guanabenz
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 12, 2026, 2:06 AM EDT
Completed No phase listed Observational

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

NCT06526000
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

NCT02634307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ALKS 8700
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
74
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 12, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

NCT00559702
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
natalizumab, standard of care
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 12, 2026, 2:06 AM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS

NCT04032171
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 12, 2026, 2:06 AM EDT
Completed No phase listed Observational

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

NCT01485003
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
44
States / cities
Homewood, Alabama • Sun City, Arizona • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 12, 2026, 2:06 AM EDT
Recruiting Not applicable Interventional

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

NCT07376772
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Interventions
wearable focal vibration therapy
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 12, 2026, 2:06 AM EDT